Kyverna Therapeutics
About Kyverna Therapeutics
KYVERNA is pioneering a new class of treatments and potential cures for serious autoimmune diseases. The company's therapeutic platform combines advanced T-cell engineering and synthetic biology technologies to suppress and eliminate the autoreactive immune cells at the root cause of inflammatory diseases.
Open positions (15)
Sr Manager, Medical Writing
Executive Director, Regulatory Affairs
Medical Science Liaison/Senior Medical Science Liaison - (Ohio Valley)
Associate Dir./Director, CAR T Channel Distribution
Director of Training, Global Medical Affairs
Vice President, Sales
Sr. Director, Marketing Promotions
Executive Director, Lifecycle Lead
Vice President, Sales
Associate Dir./Director, CAR T Channel Distribution
Executive Director, Regulatory Affairs
Sr. Director, Marketing Promotions
Medical Science Liaison/Senior Medical Science Liaison - (Southcentral)
Medical Science Liaison/Senior Medical Science Liaison - (Great Lakes)
Executive Director, Medical Writing
Company details
Funding
Total raised
$322M
Last stage
Public
Investors
Founders
Jeffrey Greve
Co-founder of Kyverna Therapeutics (formerly BAIT Therapeutics), a clinical-stage cell therapy company focused on autoimmune diseases.
Dominic Borie
MD, PhD immunologist and digestive tract/liver transplant surgeon. Appointed founding CEO of Kyverna in 2020; subsequently served as President of R&D. Previously VP at Horizon Therapeutics and held leadership roles at Genentech, Amgen, and Roche.
LinkedInWhat happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.